English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

SNAP-tagged nanobodies enable reversible optical control of a G protein-coupled receptor via a remotely tethered photoswitchable ligand

MPS-Authors
/persons/resource/persons225486

Farrants,  Helen
Chemical Biology, Max Planck Institute for Medical Research, Max Planck Society;

/persons/resource/persons203696

Johnsson,  Kai
Chemical Biology, Max Planck Institute for Medical Research, Max Planck Society;

/persons/resource/persons208663

Broichhagen,  Johannes
Chemical Biology, Max Planck Institute for Medical Research, Max Planck Society;

Fulltext (public)
There are no public fulltexts available
Supplementary Material (public)
There is no public supplementary material available
Citation

Farrants, H., Gutzeit, V. A., Ruiz, A. A., Trauner, D., Johnsson, K., Levitz, J., et al. (2018). SNAP-tagged nanobodies enable reversible optical control of a G protein-coupled receptor via a remotely tethered photoswitchable ligand. ACS Chemical Biology, 13(9), 2682-2688. doi:10.1021/acschembio.8b00628.


Cite as: http://hdl.handle.net/21.11116/0000-0001-FD42-8
Abstract
G protein-coupled receptors (GPCRs) mediate the transduction of extracellular signals into complex intracellular responses. Despite their ubiquitous roles in physiological processes and as drug targets for a wide range of disorders, the precise mechanisms of GPCR function at the molecular, cellular, and systems levels remain partially understood. In order to dissect the function of individual receptors subtypes with high spatiotemporal precision, various optogenetic and photopharmacological approaches have been reported that use the power of light for receptor activation and deactivation. Here, we introduce a novel and, to date, most remote way of applying photoswitchable orthogonally remotely-tethered ligands (PORTLs) by using a SNAP-tag fused nanobody. Our nanobody-photoswitch conjugates (NPCs) can be used to target a GFP-fused metabotropic glutamate receptor by either gene-free application of purified complexes or co-expression of genetically encoded nanobodies to yield robust, reversible control of agonist binding and subsequent downstream activation. By harboring and combining the selectivity and flexibility of both nanobodies and self-labelling enzymes, we set the stage for targeting endogenous receptors in vivo.